SG11201709782SA - Xanthine derivative - Google Patents

Xanthine derivative

Info

Publication number
SG11201709782SA
SG11201709782SA SG11201709782SA SG11201709782SA SG11201709782SA SG 11201709782S A SG11201709782S A SG 11201709782SA SG 11201709782S A SG11201709782S A SG 11201709782SA SG 11201709782S A SG11201709782S A SG 11201709782SA SG 11201709782S A SG11201709782S A SG 11201709782SA
Authority
SG
Singapore
Prior art keywords
xanthine derivative
xanthine
derivative
Prior art date
Application number
SG11201709782SA
Inventor
Yuzhe Gao
Guocheng Wang
Original Assignee
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Tasly Diyi Pharmaceutical Co Ltd filed Critical Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Publication of SG11201709782SA publication Critical patent/SG11201709782SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201709782SA 2015-05-29 2016-05-26 Xanthine derivative SG11201709782SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510290336 2015-05-29
PCT/CN2016/083406 WO2016192559A1 (en) 2015-05-29 2016-05-26 Xanthine derivative

Publications (1)

Publication Number Publication Date
SG11201709782SA true SG11201709782SA (en) 2017-12-28

Family

ID=57440191

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201709782SA SG11201709782SA (en) 2015-05-29 2016-05-26 Xanthine derivative

Country Status (15)

Country Link
US (1) US10358449B2 (en)
EP (1) EP3305787B1 (en)
JP (1) JP6742345B2 (en)
KR (1) KR20180011270A (en)
CN (2) CN106188058B (en)
AU (1) AU2016270100B2 (en)
CA (1) CA2987697A1 (en)
ES (1) ES2908658T3 (en)
HK (1) HK1245796A1 (en)
IL (1) IL255829B (en)
MY (1) MY186396A (en)
RU (1) RU2709348C2 (en)
SG (1) SG11201709782SA (en)
TW (1) TWI682931B (en)
WO (1) WO2016192559A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105983016B (en) 2015-03-23 2023-08-11 天士力医药集团股份有限公司 A pharmaceutical composition containing silybin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1496877B1 (en) * 2002-01-11 2008-10-01 Novo Nordisk A/S Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP2119717B1 (en) * 2004-02-18 2018-01-17 Boehringer Ingelheim International GmbH 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors
DE102004008112A1 (en) * 2004-02-18 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 8-aminopiperidinyl-xanthine derivatives, useful for treating e.g. diabetes, arthritis and osteoporosis, are inhibitors of dipeptidylpeptidase-IV
DE102004054054A1 (en) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
DE102005035891A1 (en) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
PE20100156A1 (en) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int NAFLD TREATMENT
UY32030A (en) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
UY32177A (en) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO
CN103172633B (en) * 2011-12-22 2016-08-03 成都地奥制药集团有限公司 A kind of compound and its production and use

Also Published As

Publication number Publication date
RU2017145919A (en) 2019-07-02
TW201643166A (en) 2016-12-16
RU2017145919A3 (en) 2019-08-09
HK1245796A1 (en) 2018-08-31
JP2018520120A (en) 2018-07-26
CN106188058B (en) 2020-11-06
IL255829B (en) 2021-02-28
MY186396A (en) 2021-07-22
CN107709324A (en) 2018-02-16
JP6742345B2 (en) 2020-08-19
EP3305787A4 (en) 2018-11-21
ES2908658T3 (en) 2022-05-03
EP3305787B1 (en) 2022-02-16
WO2016192559A1 (en) 2016-12-08
AU2016270100A1 (en) 2017-12-14
RU2709348C2 (en) 2019-12-18
US10358449B2 (en) 2019-07-23
US20180162860A1 (en) 2018-06-14
AU2016270100B2 (en) 2020-02-13
IL255829A (en) 2018-01-31
CA2987697A1 (en) 2016-12-08
KR20180011270A (en) 2018-01-31
TWI682931B (en) 2020-01-21
CN106188058A (en) 2016-12-07
EP3305787A1 (en) 2018-04-11
CN107709324B (en) 2021-06-08

Similar Documents

Publication Publication Date Title
HK1255045A1 (en) Substituted oxopyridine derivatives
IL253381A0 (en) 9h-pyrrolo-dipyridine derivatives
IL252777B (en) Dihydroindolizinone derivative
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3131898T3 (en) Fluoroalkylfluorene derivatives
IL248773A0 (en) Naphthyridinedione derivatives
PL3418273T3 (en) Flavagline derivatives
IL248629A0 (en) Cycloalkyl-linked diheterocycle derivatives
IL251005B (en) Pyrido-oxazinone derivatives
SG10201913525QA (en) Pyrimidine derivative
IL248772A0 (en) Cyclohexyl-pyridine derivative
PL3119744T3 (en) 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
HK1245796A1 (en) Xanthine derivative
HK1259107A1 (en) Aminoazole derivative
EP3444345C0 (en) microRNA-143 DERIVATIVE